Ascendis Pharma A/S (ASND)Healthcare | Biotechnology | Hellerup, Denmark | NasdaqGS
265.57 USD
+0.35
(0.132%)
⇧
(July 14, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 4:31 a.m. EDT
Ascendis Pharma presents a compelling long-term case driven by explosive 144 percent revenue growth and industry-leading profit margins, yet the low return on equity and high valuation multiples suggest the market is pricing in perfection. While the stock has delivered a massive 1259 percent return over nine years, the recent surge to near 52-week highs creates short-term overhang, especially as statistical models flag a potential pullback. There is no income component here, making this purely a growth bet. The options market reflects this tension, with traders hedging downside at current levels while maintaining bullish exposure further out. For investors, this is a high-conviction long-term hold, but a cautious short-term trade. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.066537 |
| MSTL_70_126 | 0.067180 |
| MSTL_126 | 0.067463 |
| AutoETS | 0.078548 |
| MSTL_70 | 0.080494 |
| AutoTheta | 0.081194 |
| MSTL | 0.083042 |
Forecast horizon: 60 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 43% |
| H-stat | 2.12 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.250 |
| Excess Kurtosis | -0.47 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 183.753 |
| Revenue per Share | 14.188 |
| Market Cap | 17,419,489,280 |
| Trailing P/E | 30.77 |
| Forward P/E | 25.54 |
| Profit Margins | 57.28% |
| Website | https://ascendispharma.com |
As of July 11, 2026, 4:31 a.m. EDT: Speculators are positioning for volatility with significant open interest barriers at 220 and 290 strikes. Call volume is flowing into 290 and 320 strikes, suggesting bullish bets on further upside, while put volume spiked at 280, indicating some fear of a near-term top. Implied volatility remains moderate, reflecting a balanced but tense sentiment.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.51771104 |
| Address1 | Tuborg Boulevard 12 |
| All Time High | 282.15 |
| All Time Low | 11.92 |
| Ask | 286.67 |
| Ask Size | 2 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 639,640 |
| Average Daily Volume3 Month | 775,618 |
| Average Volume | 775,618 |
| Average Volume10Days | 639,640 |
| Bid | 242.99 |
| Bid Size | 2 |
| Book Value | 8.958904 |
| City | Hellerup |
| Compensation As Of Epoch Date | 1,640,908,800 |
| Country | Denmark |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 265.57 |
| Current Ratio | 0.996 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 268.14 |
| Day Low | 263.385 |
| Debt To Equity | 183.753 |
| Earnings Call Timestamp End | 1,770,845,400 |
| Earnings Call Timestamp Start | 1,770,845,400 |
| Earnings Timestamp End | 1,777,579,200 |
| Earnings Timestamp Start | 1,777,579,200 |
| Ebitda | -10,224,000 |
| Ebitda Margins | -0.01181 |
| Enterprise To Ebitda | -1,645.033 |
| Enterprise To Revenue | 19.426 |
| Enterprise Value | 16,818,820,096 |
| Eps Current Year | 11.24614 |
| Eps Forward | 10.399448 |
| Eps Trailing Twelve Months | 8.63 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 239.2434 |
| Fifty Day Average Change | 26.326614 |
| Fifty Day Average Change Percent | 0.110041134 |
| Fifty Two Week Change Percent | 51.771103 |
| Fifty Two Week High | 282.15 |
| Fifty Two Week High Change | -16.579987 |
| Fifty Two Week High Change Percent | -0.058763023 |
| Fifty Two Week Low | 160.86 |
| Fifty Two Week Low Change | 104.71001 |
| Fifty Two Week Low Change Percent | 0.65093875 |
| Fifty Two Week Range | 160.86 - 282.15 |
| Financial Currency | EUR |
| First Trade Date Milliseconds | 1,422,455,400,000 |
| Float Shares | 62,106,626 |
| Forward Eps | 10.399448 |
| Forward P E | 25.536932 |
| Free Cashflow | 118,230,128 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 1,189 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.89037 |
| Gross Profits | 770,865,984 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00767 |
| Held Percent Institutions | 1.0241001 |
| Implied Shares Outstanding | 65,592,830 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark. |
| Long Name | Ascendis Pharma A/S |
| Market | us_market |
| Market Cap | 17,419,489,280 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_39510693 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | 495,931,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 17,376,196,595 |
| Number Of Analyst Opinions | 18 |
| Open | 265.79 |
| Operating Cashflow | 60,489,000 |
| Operating Margins | 0.10062 |
| Payout Ratio | 0.0 |
| Phone | 45 70 22 22 44 |
| Previous Close | 265.22 |
| Price Eps Current Year | 23.614326 |
| Price Hint | 2 |
| Price To Book | 29.643135 |
| Price To Sales Trailing12 Months | 20.120018 |
| Profit Margins | 0.57281 |
| Quick Ratio | 0.683 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.22222 |
| Region | US |
| Regular Market Change | 0.3500061 |
| Regular Market Change Percent | 0.13196822 |
| Regular Market Day High | 268.14 |
| Regular Market Day Low | 263.385 |
| Regular Market Day Range | 263.385 - 268.14 |
| Regular Market Open | 265.79 |
| Regular Market Previous Close | 265.22 |
| Regular Market Price | 265.57 |
| Regular Market Time | 1,784,059,200 |
| Regular Market Volume | 516,491 |
| Return On Assets | -0.00602 |
| Return On Equity | 3.32654 |
| Revenue Growth | 1.443 |
| Revenue Per Share | 14.188 |
| Sand P52 Week Change | 0.20365608 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 65,592,830 |
| Shares Percent Shares Out | 0.05 |
| Shares Short | 3,277,898 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 1,720,143 |
| Short Name | Ascendis Pharma A/S |
| Short Percent Of Float | 0.0592 |
| Short Ratio | 3.52 |
| Source Interval | 15 |
| Symbol | ASND |
| Target High Price | 348.31107 |
| Target Low Price | 248.37044 |
| Target Mean Price | 299.04102 |
| Target Median Price | 295.62634 |
| Total Cash | 572,819,968 |
| Total Cash Per Share | 9.222 |
| Total Debt | 896,664,000 |
| Total Revenue | 865,779,008 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 8.63 |
| Trailing P E | 30.772886 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 222.53203 |
| Two Hundred Day Average Change | 43.03798 |
| Two Hundred Day Average Change Percent | 0.19340128 |
| Type Disp | Equity |
| Volume | 516,491 |
| Website | https://ascendispharma.com |
| Zip | 2,900 |